Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure

FASEB Journal

Volumn 15, Issue 10, 2001, Pages 1718-1726

  Senzaki, Hideaki ^a   Smith, Carolyn J ^b   Juang, George J ^a   Isoda, Takayoshi ^a   Mayer, Sharon P ^b   Ohler, Andreas ^a   Paolocci, Nazareno ^a   Tomaselli, Gordon F ^a   Hare, Joshua M ^a   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Coronary blood flow; PDE5; Protein expression; Tissue activity

Indexed keywords

CYCLIC GMP; DOBUTAMINE; PHOSPHODIESTERASE; PYRAZOLINE DERIVATIVE;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; DOG; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME SPECIFICITY; FEMALE; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ADENYLATE CYCLASE; ADRENERGIC BETA-AGONISTS; ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT, LOW; CYCLIC GMP; DOBUTAMINE; DOGS; FEMALE; FORSKOLIN; HEART; HEMODYNAMIC PROCESSES; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINONES; PYRAZOLES; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

ANIMALIA; CANIS FAMILIARIS; LEPUS;

EID: 17844381569     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0538com     Document Type: Article

References (47)

1. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: Coupling of both receptor sub_types to muscle contraction and selective beta 1-receptor down-regulation in heart failure
2. Reduced beta 1 receptor messenger RNA abundance in the failing human heart
3. β-Adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing
4. Exploring the role of the beta-adrenergic receptor kinase in cardiac disease using gene-targeted mice
5. 2+ in intact cardiac myocytes
6. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes
7. The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials
8. BNP: Increasing importance in the pathophysiology and diagnosis of congestive heart failure
9. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: Potentiation of beta-adrenergic inotropic responsiveness
10. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction
11. Regulation of cardiac beta-adrenergic response by nitric oxide
12. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure
13. The molecular biology of cyclic nucleotide phosphodiesterases
14. Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3′,5′-cyclic nucleotide phosphodiesterase
15. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
16. Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5)
17. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases
18. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A
19. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A
20. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase
21. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)
22. Cyclic GMP phosphodiesterase-5: Target of sildenafil
23. Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats
24. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise
25. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro
26. Novel alternative splice variants of cGMP-binding cGMP-specific phosphodiesterase
27. Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene
28. Improved mechanoenergetics and cardiac rest and reserve function of in vivo failing heart by calcium sensitizer EMD-57033
29. Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure
30. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts
31. Downregulation of right ventricular phosphodiesterase PDE-3A mRNA and protein before the development of canine heart failure
32. Development of decompensated dilated cardiomyopathy is associated with decreased gene expression and activity of the milrinone-sensitive cAMP phosphodiesterase PDE3A
33. Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase-1 in heart failure
34. Effects of sildenafil citrate on human hemodynamics
35. Differential hemodynamic responses to selective inhibitors of cyclic nucleotide phosphodiesterases in conscious rats
36. Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues
37. Myocardial contractile response to nitric oxide and cGMP
38. Inducible nitric oxide synthase (iNOS) in the human heart: Expression and localization in congestive heart failure
39. Expression of inducible nitric oxide synthase in human heart failure
40. The negative inotropic effect of beta3-adrenoceptor stimulation is mediated by activation of a nitric oxide synthase pathway in human ventricle
41. 3-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility
42. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities
43. Phosphorylation and activation of cGMP-dependent protein kinase by Src
44. Genomic origin and transcriptional regulation of two variants of cGMP-binding cGMP-specific phosphodiesterases
45. Cyclic GMP protein kinase mediates negative metabolic and functional effects of cyclic GMP in control and hypertrophied rabbit cardiac myocytes
46. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts
47. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase